StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Solifenacin

HCID 154059
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
242478-37-1
Standard-SMILES
O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1
InChIKey
FBOUYBDGKBSUES-VXKWHMMOSA-N
Summenformel
C23H26N2O2
Durchschnittliche Molmasse
362,5 g/mol
Monoisotopische Masse
362,19942808

Überblick

Solifenacin is a member of isoquinolines.

Namen und Bezeichner

Bevorzugter Name
Solifenacin
IUPAC
[(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate
Englischer Name
Solifenacin
Summenformel
C23H26N2O2
Molmasse
362.46

Namen und Synonyme

Solifenacin242478-37-1solifenacineSolifenacinaA8910SQJ1U[(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylateNSC-759144DTXSID3048289(3R)-1-azabicyclo[2.2.2]octan-3-yl (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate((8r)-1-azabicyclo(2.2.2)octan-8-yl) (1s)-1-phenyl-3,4-dihydro-1h-isoQUINOLINE-2-carboxylate2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,1-azabicyclo(2.2.2)oct-3-yl ester, (R-(R*,S*))-solifenacinum
Weitere Namen anzeigen
YM 905SolinaxinSofina NewSolif·NacinUnii-A8910sqj1uSolifenacin BaseSolifenacin (YM905)Solifenacin [inn:ban]4R-Hydroxy Solifenacin
((3R)-1-azabicyclo(2.2.2)octan-3-yl) (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate(3R)-1-azabicyclo(2.2.2)octan-3-yl (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate[(8R)-1-azabicyclo[2.2.2]octan-8-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylateRefChem:56468DTXCID8028264G04BD08Soliten(+)-Solifenacin

Eigenschaften

Berechnete Struktureigenschaften

XLogP
4
Polarare Oberfläche (TPSA)
32,8 Ų
H-Brücken-Donoren
0
H-Brücken-Akzeptoren
3
Frei drehbare Bindungen
3
Schwere Atome
27
Formalladung
0
Komplexität
524

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
Human DrugsBreast Feeding; Lactation; Muscarinic Antagonists; Parasympatholytics
Melting Point134-136
Collision Cross Section179.96 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physikochemische Eigenschaften

Siedepunkt
505.5 · 505.5±50.0 °C(Predicted)
Dichte
1.24 · 1.24±0.1 g/cm3(Predicted)
storage temp.
-20 °C · Store at -20°C
Löslichkeit
50 mg/mL · DMSO : ≥ 50 mg/mL (137.95 mM);Water : < 0.1 mg/mL (insoluble)
Aggregatzustand
Solid
pka
9.03 · 9.03±0.33(Predicted)
Farbe
White to off-white

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

Toxikologische Informationen

Hepatotoxicity · 1 Eintrag

Like most anticholinergic agents, solifenacin has not been linked to liver enzyme elevations during therapy or to instances of clinically apparent liver injury with jaundice. In multiple prospective clinical trials of solifenacin in patients with overactive bladder syndrome, ALT elevations were reported in less than 1% of treated subjects, rates similar to that of placebo-recipients. Despite widespread clinical use for almost two decades, there has been only a single published case report of possible liver injury due to darifenacin use. An elderly woman with end stage liver injury developed transient elevations of serum aminotransferases and alkaline phosphatase without jaundice two weeks after starting solifenacin. Thus, liver injury due to solifenacin must be rare if it occurs at all.

Drug Induced Liver Injury · 5 Einträge

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

solifenacin

DILI Negative

Oral

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

Alarmwort
Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code H302

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 3 Einträge

G04BD08

G - Genito urinary system and sex hormones

QG - Genito urinary system and sex hormones

Protein BindingSolifenacin is 93-96% protein bound in plasma, mainly to alpha-1-acid glycoprotein.
Pharmacodynamics · 1 Eintrag

Solifenacin antagonizes the M2 and M3 muscarinic receptors in the bladder to treat an overactive bladder. It has a long duration of action as it is usually taken once daily. Patients taking solifenacin should be aware of the risks of angioedema and anaphylaxis.

Mechanism of Action · 1 Eintrag

Solifenacin is a competitive muscarinic receptor antagonist. It has the highest affinity for M3, M1, and M2 muscarinic receptors. 80% of the muscarinic receptors in the bladder are M2, while 20% are M3. Solifenacin's antagonism of the M3 receptor prevents contraction of the detrusor muscle, while antagonism of the M2 receptor may prevent contraction of smooth muscle in the bladder.

Biological Half-LifeThe elimination half life of solifenacin ranges from 33-85 hours.
Metabolism/Metabolites · 1 Eintrag

Solifenacin undergoes N-oxidation at the quinuclidin ring by cytochrome P450, though the exact enzymes are not revealed in the literature. The tetrahydroisoquinolone ring is 4R-hydroxylated by CYP3A4, CYP1A1, and CYP2D6. A 4R-hydroxy N-oxide metabolite is also formed by CYP3A4. Finally, solifenacin can undergo direct glucuronidation. Only solifenacin and the 4R-hydroxy metabolite are pharmacologically active.

FDA Pharmacological Classification · 5 Einträge

A8910SQJ1U

SOLIFENACIN

Established Pharmacologic Class [EPC] - Cholinergic Muscarinic Antagonist

Mechanisms of Action [MoA] - Cholinergic Muscarinic Antagonists

Solifenacin is a Cholinergic Muscarinic Antagonist. The mechanism of action of solifenacin is as a Cholinergic Muscarinic Antagonist.

Zugehörige Reaktionen

12
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 1056487
HRID 1056487als Produkt
Reaktionsgleichung von HRID 1171848
HRID 1171848als Produkt
Reaktionsgleichung von HRID 1171849
HRID 1171849als Edukt
Reaktionsgleichung von HRID 1171852
HRID 1171852als Produkt
Reaktionsgleichung von HRID 1171854
HRID 1171854als Produkt
Reaktionsgleichung von HRID 1171856
HRID 1171856als Produkt
Reaktionsgleichung von HRID 1616251
HRID 1616251als Edukt
Reaktionsgleichung von HRID 1616252
HRID 1616252als Edukt
ZurückSeite 1 von 2

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung

Datenbank-Bezeichner

CAS
242478-37-1
PubChem CID
154059
DTXSID
DTXSID3048289
ChEMBL
CHEMBL1734
ChEBI
CHEBI:135530
UNII
A8910SQJ1U
Nikkaji
J1.594.869H
MeSH Pharmacological Classification · 2 Einträge

Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system.

Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS.

Absorption, Distribution and Excretion · 4 Einträge

Solifenacin is well absorbed in the duodenum, jejunum, and ileum but not the stomach. Absorption occurs via passive diffusion and so no transporters are involved. The mean oral bioavailability of solifenacin is 88%. The Tmax of solifenacin is 3-8 hours with a Css of 32.3ng/mL for a 5mg oral dose and 62.9ng/mL for a 10mg oral dose.

69.2±7.8% of a radiolabelled dose is recovered in the urine, 22.5±3.3% was recovered in feces, and 0.4±7.8% was recovered in exhaled air. 18% of solifenacin is eliminated as the N-oxide metabolite, 9% is eliminated as the 4R-hydroxy N-oxide metabolite, and 8% is eliminated as the 4R-hydroxy metabolite.

The volume of distribution of solifenacin is 600L.

The clearance of solifenacin is 7-14L/h and a renal clearance of 0.67-1.51L/h.

Verwendung und Herstellung

UsesUse (kg; approx.) in Germany (2009): >100

Anwendungen

Verwendenmuscarinic M3 antagonist

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

(R)-Chinuclidin-3-olEthyl (S)-1-phenyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate

Nachgelagerte Produkte

Solifenacin N-Oxide